Suboxone is the brand most people mean when they say buprenorphine. It is a sublingual or buccal film that combines buprenorphine, a partial opioid agonist, with naloxone, and it is one of the most effective treatments medicine has for opioid use disorder. None of what follows is an argument against the drug. The benefit, in a condition that kills tens of thousands of people a year, is not seriously in dispute. The dispute is narrower and more specific: whether the people taking it were warned that the film could destroy their teeth.

SECTION 01What the FDA actually said

On January 12, 2022, the Food and Drug Administration issued a Drug Safety Communication about dental problems tied to buprenorphine medicines that dissolve in the mouth. The list was not limited to ordinary cavities. It included tooth decay, dental abscesses and infection, tooth erosion, and in some cases total tooth loss. The agency noted that these problems had been reported even in patients with no prior history of dental disease, and that some were serious enough to require extraction, root canals, crowns, or dentures.

The FDA was careful to keep the benefit-risk message intact: the agency stated plainly that the benefits of these medicines continue to outweigh the risks for opioid use disorder and pain. The recommendation was not to stop the drug. It was to add a known hazard to the label and to give patients ways to protect their teeth.

SECTION 02Why the mouth, and not the bloodstream

The most telling detail in the FDA review is what was not flagged. Buprenorphine also comes as a transdermal patch and as a long acting injection. Neither of those routes generated the dental signal. Only the formulations that dissolve in contact with the teeth did. That pattern points away from a systemic, whole-body effect and toward something happening locally, right at the enamel.

The leading proposed mechanism is acidity. The films are formulated at a low pH to help the drug absorb across the lining of the mouth. Each dose sits and dissolves against the teeth for several minutes, often twice a day, for months or years. Enamel begins to demineralize once the surface pH drops below roughly 5.5, so a repeated acid bath in the same spot is a plausible route to erosion. Buprenorphine can also reduce salivary flow, and saliva is the mouth’s natural buffer and remineralizing system. Less saliva, lower pH, and prolonged contact is a combination dentists already associate with rapid decay.

The teeth that dissolve the medicine are the teeth that pay for it. Route of administration, not the molecule alone, is where this case lives.

SECTION 03What the evidence does and does not prove

Honesty about the science cuts both ways. Most of the early evidence came from spontaneous adverse event reports, which establish a signal but not causation, and people who use opioids carry a higher baseline rate of dental disease for reasons that have nothing to do with any one drug. A defense expert will press hard on that confounding, and a careful analysis has to account for it.

That said, the signal has held up under more rigorous looks. A 2022 cohort study published in JAMA compared patients on sublingual buprenorphine and naloxone against patients on transdermal buprenorphine and oral naltrexone, and found a statistically significant increase in dental disease in the group whose medicine dissolved in the mouth. Pharmacovigilance analyses of the FDA reporting database have found disproportionately high dental reporting for the sublingual route specifically, well above what the comparison drugs produced. The route specificity is the throughline: it appears in the FDA data, in the cohort comparison, and in the reporting database alike.

SECTION 04Where the litigation stands

The claims have been consolidated as multidistrict litigation, In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092, before Judge J. Philip Calabrese in the Northern District of Ohio. The Judicial Panel centralized the cases in early 2024, and the docket has grown to more than eleven thousand filed actions against Indivior and its predecessor. The core allegation is a failure to warn: that the manufacturer knew or should have known of the dental risk well before 2022 and did not update the label. The manufacturer’s principal defense is federal preemption, arguing it could not lawfully change the warning earlier. The court has set a bellwether schedule, with representative trials currently projected to begin in 2028. No global settlement has been approved.

SECTION 05The forensic questions that decide these cases

From a toxicology and causation standpoint, a Suboxone dental claim is not won by the FDA warning alone. It is won or lost on the individual record. The questions below are the ones that separate a documented injury from an assumed one, and they are the ones a forensic review is built to answer.

This article is general information on a matter of pharmacology and product liability. It is not medical advice and not legal advice, and it does not create an attorney client relationship. No one should start, stop, or change a buprenorphine prescription based on this piece. Treatment decisions for opioid use disorder should be made with a qualified clinician.

Primary sources: FDA Drug Safety Communication, January 12, 2022; Etminan et al., JAMA, 2022; FDA Adverse Event Reporting System pharmacovigilance analyses; In re: Suboxone Film Products Liability Litigation, MDL No. 3092, N.D. Ohio.